KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBIT (2019 - 2025)

Historic EBIT for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $14.6 million.

  • GoodRx Holdings' EBIT fell 2835.79% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.0 million, marking a year-over-year increase of 18248.69%. This contributed to the annual value of $65.8 million for FY2024, which is 34381.09% up from last year.
  • GoodRx Holdings' EBIT amounted to $14.6 million in Q3 2025, which was down 2835.79% from $26.8 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year EBIT high stood at $26.8 million for Q2 2025, and its period low was -$38.3 million during Q3 2023.
  • For the 5-year period, GoodRx Holdings' EBIT averaged around $6.3 million, with its median value being $11.3 million (2023).
  • Examining YoY changes over the last 5 years, GoodRx Holdings' EBIT showed a top increase of 55238.45% in 2023 and a maximum decrease of 115284.97% in 2023.
  • Over the past 5 years, GoodRx Holdings' EBIT (Quarter) stood at $11.8 million in 2021, then crashed by 85.22% to $1.7 million in 2022, then tumbled by 1152.85% to -$18.3 million in 2023, then surged by 199.41% to $18.2 million in 2024, then dropped by 19.58% to $14.6 million in 2025.
  • Its EBIT stands at $14.6 million for Q3 2025, versus $26.8 million for Q2 2025 and $23.4 million for Q1 2025.